Refractory Acute Myeloid Leukemia clinical trials

Explore recruiting refractory acute myeloid leukemia clinical trials.

Recruiting refractory acute myeloid leukemia studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Refractory Acute Myeloid Leukemia trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

IMPACT-AML: A RANDOMIZED PRAGMATIC CLINICAL TRIAL FOR RELAPSE OR REFRACTORY ACUTE MYELOID LEUKEMIA

Germany, Czechia, Italy, Lithuania, Spain, Portugal +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

France, Germany

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

MAATEO: A phase 1 study in patients with hematological malignancies to evaluate safety, tolerability and efficacy of Karonudib

Sweden, Denmark

Phase I and Phase II (Integrated)- Other EU CTIS Study details

A Phase 1 Study of JNJ-89853413 for Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Neoplasms

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).

Spain, Hungary, Czechia, France, Italy, Belgium

Human Pharmacology (Phase I)- Other EU CTIS Study details

A Dose Finding Phase 1 Study of CC-96191 in Subjects with Relapsed or Refractory Acute Myeloid Leukemia

France

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

Refractory Acute Myeloid Leukemia trials by city

Refractory Acute Myeloid Leukemia in Toronto Refractory Acute Myeloid Leukemia in Vancouver Refractory Acute Myeloid Leukemia in Montreal Refractory Acute Myeloid Leukemia in Calgary Refractory Acute Myeloid Leukemia in Edmonton Refractory Acute Myeloid Leukemia in Ottawa Refractory Acute Myeloid Leukemia in Winnipeg Refractory Acute Myeloid Leukemia in Quebec City Refractory Acute Myeloid Leukemia in Hamilton Refractory Acute Myeloid Leukemia in Kitchener Refractory Acute Myeloid Leukemia in London Refractory Acute Myeloid Leukemia in Halifax Refractory Acute Myeloid Leukemia in New York Refractory Acute Myeloid Leukemia in Los Angeles Refractory Acute Myeloid Leukemia in Chicago Refractory Acute Myeloid Leukemia in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease